# Michael Sidler

> Michael Sidler is a seed investor at The Swiss Private Equity & Corporate Finance Association backing Health Care. See 15 investments, check sizes…

- Type: Angel Investor
- Fund: [The Swiss Private Equity & Corporate Finance Association](https://shizune.co/investors/profile/the-swiss-private-equity-corporate-finance-association)
- Location: Zurich, Switzerland
- Total investments: 15
- Last investment: Oct 2025
- Lead investor: 53%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sidler/
- X (Twitter): http://twitter.com/michael_sidler
- Website: https://x.com/michael_sidler

Michael Sidler is a seed investor at The Swiss Private Equity & Corporate Finance Association in Zurich focused on Health Care and Biotechnology. Passionate investor, coach and supporter of startups and the whole ecosystem around them. GP at Redalpine

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 20% |
| Biotechnology | 3 | 20% |
| Wellness | 2 | 13% |
| Therapeutics | 2 | 13% |
| Medical Device | 2 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 27% |
| Series A | 3 | 20% |
| Series B | 2 | 13% |
| Series C | 1 | 7% |
| Series D | 1 | 7% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 3 | 20% |
| Germany | 2 | 13% |
| United Kingdom | 2 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Valink Therapeutics | Valink Therapeutics is a health care drug discovery for next-generation cancer treatments. | $11.8M | Seed | Oct 20, 2025 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $42M | Series B | May 01, 2025 |  |
| Dunia Innovation | Dunia Innovation is a creating the world's first self-driving laboratory for electrocatalytic CO2 utilization, which will drastically accelerate catalyst research. | $11.5M | Venture - Series Unknown | Oct 23, 2024 |  |
| Dunia Innovation | Dunia Innovation is a creating the world's first self-driving laboratory for electrocatalytic CO2 utilization, which will drastically accelerate catalyst research. |  | Seed | Oct 23, 2024 |  |
| ExpressionEdits | ExpressionEdits operates in the biotechnology industry, focusing on the redesign of synthetic DNA instructions. The company utilizes an AI-driven approach to redefine the status quo of protein expression. It is involved in building biology similar to nature. The team at ExpressionEdits includes scientists and engineers who are dedicated todeveloping new technologies. Proteins, a foundational pillar in healthcare and behind every major advancement in biotech and synthetic biology, are at the core of their work. | $13M | Seed | May 29, 2024 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $30.7M | Series A | Feb 27, 2024 |  |
| Lunaphore | Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $32.7M | Series D | Mar 23, 2023 |  |
| Sanity Group | Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $37.6M | Series B | Sep 07, 2022 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $17.5M | Series A | Nov 02, 2021 |  |
| Sanity Group | Sanity Group is a holistic European Cannabis company focusing on health, wellbeing, and scientific research. To utilize the full potential of its health benefits, Sanity Group is investing in fundamental research of the cannabis plant and its active ingredients as well as in specific areas of application.It was founded in 2018 and headquarteredin Berlin, Germany. | $44.2M | Series A | Jun 15, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [Translink Capital](https://shizune.co/investors/profile/translink-capital) — VC Fund, 5 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 4 deals together
- [Molten Ventures](https://shizune.co/investors/profile/draper-esprit) — VC Fund, 3 deals together
- [OCCIDENT](https://shizune.co/investors/profile/occident-group) — VC Fund, 3 deals together
- [415 Capital](https://shizune.co/investors/profile/415-capital-management) — VC Fund, 2 deals together
- [Alpana Ventures](https://shizune.co/investors/profile/alpana-ventures) — VC Fund, 2 deals together

## About The Swiss Private Equity & Corporate Finance Association

VC Fund

The Swiss Private Equity & Corporate Finance Association (SECA) is the representative body for Switzerland‘s private equity, venture capital and corporate finance industries. SECA has the objective to promote private equity and corporate finance activities in Switzerland. Members of the SECA include equity investment companies, banks, corporatefinance advisors, auditing companies, management consultants, lawyers and private investors. For more information about SECA, please visit www.seca.ch.With this group, they want to keep our members up-to-date about the the most recent news, events, projects, etc. Furthermore, they strive to achieve some interaction between you, all the other members of this group and SECA. Therefore, please do not hesitate to post content, which might be of interest to your fellow group members. Moreover, if you have any colleagues, who are interested in SECA or the industries they are representing, please recommend this group to them.

2 contacts available at The Swiss Private Equity & Corporate Finance Association.

| Name | Title | Profile |
| --- | --- | --- |
| Maurice Pedergnana | General Secretary | https://shizune.co/investors/profile/maurice-pedergnana |
| Michael Sidler | Chair Chapter Seed & Venture Capital | https://shizune.co/investors/profile/michael-sidler |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Michael Sidler invest in?

Michael Sidler invests primarily in Health Care, Biotechnology and Wellness startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michael Sidler last invest?

The most recent investment recorded for Michael Sidler closed in Oct 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co